PDCD1 and renal cell adenocarcinoma: By removing inhibitory effects of PD-1/PD-L1 pathway, PD-1/PD-L1 blocker enhance antitumor immune responses and exhibit optimal therapeutic efficacy in various tumor types, including melanoma [55], non-small-cell lung cancer [56] and renal-cell cancer [57].